CO2019014090A2 - Agentes, usos y métodos para el tratamiento - Google Patents
Agentes, usos y métodos para el tratamientoInfo
- Publication number
- CO2019014090A2 CO2019014090A2 CONC2019/0014090A CO2019014090A CO2019014090A2 CO 2019014090 A2 CO2019014090 A2 CO 2019014090A2 CO 2019014090 A CO2019014090 A CO 2019014090A CO 2019014090 A2 CO2019014090 A2 CO 2019014090A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- agents
- methods
- antibodies
- pgrn
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 102000019204 Progranulins Human genes 0.000 abstract 2
- 108010012809 Progranulins Proteins 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
RESUMEN La presente invención se refiere a anticuerpos monoclonales anti-sortilina que se ha encontrado que son útiles en la corrección de un nivel deficiente de progranulina (PGRN). En particular, estos anticuerpos pueden usarse en el tratamiento de la demencia frontotemporal (DFT) y la esclerosis lateral amiotrófica (ELA) y otros trastornos neurodegenerativos, tales como la enfermedad de Alzheimer (EA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700419 | 2017-07-20 | ||
PCT/EP2018/069460 WO2019016247A2 (en) | 2017-07-20 | 2018-07-18 | AGENTS, USES AND METHODS OF TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019014090A2 true CO2019014090A2 (es) | 2020-01-17 |
Family
ID=63113476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0014090A CO2019014090A2 (es) | 2017-07-20 | 2019-12-13 | Agentes, usos y métodos para el tratamiento |
Country Status (25)
Country | Link |
---|---|
US (2) | US10894833B2 (es) |
EP (1) | EP3655438A2 (es) |
JP (1) | JP2020527152A (es) |
KR (1) | KR20200031610A (es) |
CN (1) | CN110945029A (es) |
AR (1) | AR112563A1 (es) |
AU (1) | AU2018303175A1 (es) |
BR (1) | BR112019005428A2 (es) |
CA (1) | CA3069391A1 (es) |
CL (1) | CL2020000070A1 (es) |
CO (1) | CO2019014090A2 (es) |
CR (1) | CR20200027A (es) |
DO (1) | DOP2020000006A (es) |
EA (1) | EA201992688A1 (es) |
EC (1) | ECSP20002935A (es) |
IL (1) | IL271728B2 (es) |
JO (1) | JOP20200007A1 (es) |
MA (1) | MA49633A (es) |
NI (1) | NI202000005A (es) |
PE (1) | PE20210467A1 (es) |
PH (1) | PH12019502869A1 (es) |
RU (1) | RU2019140933A (es) |
SG (1) | SG11201912228WA (es) |
TW (1) | TW201908342A (es) |
WO (1) | WO2019016247A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
BR112019022666A2 (pt) | 2018-07-13 | 2020-09-01 | Alector Llc | anticorpos antissortilina e métodos de uso dos mesmos |
SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
WO2023247754A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
PT804070E (pt) | 1993-03-09 | 2000-11-30 | Genzyme Corp | Isolamento de componentes de interesse a partir do leite. |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
DK1150918T3 (da) | 1999-02-03 | 2004-12-20 | Biosante Pharmaceuticals Inc | Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
KR20020047098A (ko) | 1999-07-29 | 2002-06-21 | 추후제출 | HER2/neu에 대한 인간 모노클로날 항체 |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
AU2003287930A1 (en) | 2002-12-20 | 2004-07-14 | Neuronicon Aps | Modulation of activity of neurotrophins |
KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
PT2120997T (pt) | 2006-12-21 | 2017-05-05 | H Lundbeck As | Modulação da atividade de proneurotrofinas |
EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
CA2712276A1 (en) * | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
JP5715045B2 (ja) | 2008-04-27 | 2015-05-07 | ハー・ルンドベック・アクチエゼルスカベット | ソルチリンに対する特異的リガンドの設計 |
WO2009154995A2 (en) * | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
US8703125B2 (en) | 2008-12-19 | 2014-04-22 | H. Lundbeck A/S | Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders |
WO2014071131A1 (en) | 2012-11-02 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
US10149836B2 (en) * | 2014-03-21 | 2018-12-11 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
KR102555955B1 (ko) * | 2014-03-27 | 2023-07-18 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
EP4116328A1 (en) * | 2017-04-05 | 2023-01-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination therapies targeting pd-1, tim-3, and lag-3 |
BR112019022666A2 (pt) * | 2018-07-13 | 2020-09-01 | Alector Llc | anticorpos antissortilina e métodos de uso dos mesmos |
CN113151432A (zh) * | 2020-04-14 | 2021-07-23 | 郁金泰 | 神经退行性疾病检测和治疗的新靶标 |
-
2018
- 2018-07-17 US US16/037,790 patent/US10894833B2/en active Active
- 2018-07-18 PE PE2020000100A patent/PE20210467A1/es unknown
- 2018-07-18 SG SG11201912228WA patent/SG11201912228WA/en unknown
- 2018-07-18 IL IL271728A patent/IL271728B2/en unknown
- 2018-07-18 BR BR112019005428A patent/BR112019005428A2/pt not_active IP Right Cessation
- 2018-07-18 RU RU2019140933A patent/RU2019140933A/ru unknown
- 2018-07-18 CA CA3069391A patent/CA3069391A1/en active Pending
- 2018-07-18 JP JP2020502415A patent/JP2020527152A/ja active Pending
- 2018-07-18 MA MA049633A patent/MA49633A/fr unknown
- 2018-07-18 KR KR1020207001250A patent/KR20200031610A/ko not_active Application Discontinuation
- 2018-07-18 CN CN201880047918.8A patent/CN110945029A/zh active Pending
- 2018-07-18 JO JOP/2020/0007A patent/JOP20200007A1/ar unknown
- 2018-07-18 EA EA201992688A patent/EA201992688A1/ru unknown
- 2018-07-18 WO PCT/EP2018/069460 patent/WO2019016247A2/en unknown
- 2018-07-18 AU AU2018303175A patent/AU2018303175A1/en active Pending
- 2018-07-18 CR CR20200027A patent/CR20200027A/es unknown
- 2018-07-18 EP EP18750343.8A patent/EP3655438A2/en active Pending
- 2018-07-19 TW TW107124976A patent/TW201908342A/zh unknown
- 2018-07-20 AR ARP180102043 patent/AR112563A1/es unknown
-
2019
- 2019-12-13 CO CONC2019/0014090A patent/CO2019014090A2/es unknown
- 2019-12-18 PH PH12019502869A patent/PH12019502869A1/en unknown
-
2020
- 2020-01-09 DO DO2020000006A patent/DOP2020000006A/es unknown
- 2020-01-09 CL CL2020000070A patent/CL2020000070A1/es unknown
- 2020-01-16 EC ECSENADI20202935A patent/ECSP20002935A/es unknown
- 2020-01-17 NI NI202000005A patent/NI202000005A/es unknown
- 2020-12-11 US US17/118,934 patent/US20210292414A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110945029A (zh) | 2020-03-31 |
PE20210467A1 (es) | 2021-03-08 |
CR20200027A (es) | 2020-04-17 |
PH12019502869A1 (en) | 2020-09-28 |
CA3069391A1 (en) | 2019-01-24 |
AU2018303175A1 (en) | 2020-01-16 |
US20210292414A1 (en) | 2021-09-23 |
IL271728B2 (en) | 2024-05-01 |
AR112563A1 (es) | 2019-11-13 |
RU2019140933A (ru) | 2021-08-20 |
KR20200031610A (ko) | 2020-03-24 |
BR112019005428A2 (pt) | 2019-07-16 |
MA49633A (fr) | 2020-05-27 |
US10894833B2 (en) | 2021-01-19 |
CL2020000070A1 (es) | 2020-06-12 |
NI202000005A (es) | 2020-05-20 |
WO2019016247A2 (en) | 2019-01-24 |
US20190023788A1 (en) | 2019-01-24 |
ECSP20002935A (es) | 2020-02-28 |
EA201992688A1 (ru) | 2020-05-20 |
IL271728A (en) | 2020-02-27 |
WO2019016247A3 (en) | 2019-06-20 |
JP2020527152A (ja) | 2020-09-03 |
RU2019140933A3 (es) | 2021-10-28 |
DOP2020000006A (es) | 2020-07-15 |
TW201908342A (zh) | 2019-03-01 |
JOP20200007A1 (ar) | 2020-01-15 |
EP3655438A2 (en) | 2020-05-27 |
IL271728B1 (en) | 2024-01-01 |
SG11201912228WA (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019014090A2 (es) | Agentes, usos y métodos para el tratamiento | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
MA44322A (fr) | Compositions comprenant des souches bactériennes | |
MA42471A (fr) | Compositions comprenant des souches bactériennes | |
DOP2016000195A (es) | Compuestos | |
GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
UY37808A (es) | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 | |
MD3261720T2 (ro) | Anticorpi anti-Tau și utilizările acestora | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
UY37580A (es) | Compuestos novedosos que inhiben la actividad de cinasa lrrk2 | |
MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
MX2021005502A (es) | Composiciones y metodos para tratar enfermedades neurodegenerativas. | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
MX2017006692A (es) | Trastornos neurodegenerativos. | |
MX2020006140A (es) | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. | |
MX2019001804A (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
MX2021001287A (es) | Métodos para tratar trastornos neurodegenerativos. | |
MA40908B1 (fr) | Anticorps anti-il-6 améliorés | |
EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний |